MyFinsight
Home
Blog
About
Contact
Download
Download image
Comprehensive loss
-$111,439K
Net loss
-$109,524K
Total other
comprehensive (loss)
-$1,915K
Income tax (benefit)
expense
-$1,033K
Unrealized holding gain on
marketable securities
$316K
Other income, net
$8,556K
Interest income
$5,789K
Foreign currency
exchange gain
$30K
Loss before income
tax (benefit)...
-$110,557K
Reclassification adjustment for
realized holding gain on...
$1,227K
Foreign currency
translation loss
-$1,004K
Total other income
$1,480K
Commercial expenses
$89,441K
Interest expense
$12,895K
Other sg&a
$35,780K
Clinical development
$14,723K
Research expenses
$12,851K
Regulatory and qa expenses
$5,239K
Cost of product and
service sold
$3,081K
Operating loss
-$112,037K
Product revenue, net
$49,078K
Net loss
-$109,524K
Total other income
-$1,480K
Income tax expense
(benefit), total
-$1,033K
Total operating
expenses
$161,115K
Segment net loss
-$109,524K
Selling, general and
administrative
$124,663K
Research and development
$33,371K
Cost of revenue
$3,081K
Back
Back
Income Statement
source: myfinsight.com
KalVista Pharmaceuticals, Inc. (KALV)
KalVista Pharmaceuticals, Inc. (KALV)